Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE III STUDIES

Intervention/treatment:
RO5490261 (ETROLIZUMAB)/ AZATHIOPRINE
Medical condition:
ULCERATIVE COLITIS
Protocol code:
GA28951
Control number:
174681
Status:
Closed
Approved:
June 11, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02118584
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Medical Communications
Organization
Hoffmann-La Roche
Phone:
800 821-8590
Sponsor
HOFFMANN-LA ROCHE LIMITED

Locations

Alberta

University of Calgary
Calgary, Alberta, T2N 2T9
Zeidler Ledcor Centre - University of Alberta; Division of Gasroenterology
Edmonton, Alberta, T6G 2X8

British Columbia

Pacific Gastroenterology Associates
Vancouver, British Columbia, V6Z 2K5

Nova Scotia

Queen Elizabeth II Health Sciences Centre; Gastroenterology Research
Halifax, Nova Scotia, B3H 1V7

Ontario

Guelph GI & Surgery Clinic
Guelph, Ontario, N1H 3R3
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5
Taunton Health Centre
Oshawa, Ontario, L1H 7K4
Toronto Digestive Disease Associates
Vaughan, Ontario, L4L 4Y7
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
University Hospital - London Health Sciences Centre
London, Ontario, N6A 5A5

Quebec

Centre de santé et de services sociaux Champlain-Charles-Le Moyne
Greenfield Park, Quebec, J4V 2H1
Hotel Dieu de Levis
Lévis, Quebec, G6V 3Z1
Hôpital Maisonneuve - Rosemont
Montreal, Quebec, H1T 2M4

Saskatchewan

Royal University Hospital
Saskatoon, Saskatchewan, S7N 0W8

Results

See the results from the trial NCT02118584. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?